Amicus Therapeutics - FOLD Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings or view top-rated stocks.

5 brokerages have issued 12-month price targets for Amicus Therapeutics' stock. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they anticipate the company's share price to reach $15.20 in the next year. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts.

Amicus Therapeutics' stock was trading at $12.21 at the beginning of the year. Since then, FOLD shares have decreased by 8.8% and is now trading at $11.14.
View the best growth stocks for 2023 here.

Amicus Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 20,880,000 shares, an increase of 15.4% from the February 28th total of 18,090,000 shares. Based on an average trading volume of 2,120,000 shares, the short-interest ratio is presently 9.8 days.
View Amicus Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our FOLD earnings forecast.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.01. The biopharmaceutical company had revenue of $79.55 million for the quarter, compared to analysts' expectations of $81.42 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 141.73% and a negative net margin of 71.83%. During the same quarter in the previous year, the company earned ($0.22) EPS.

ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), iShares U.S. Pharmaceuticals ETF (IHE), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Amicus Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $329.00 million-$329.00 million, compared to the consensus revenue estimate of $326.68 million.

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (6.35%), JPMorgan Chase & Co. (4.82%), Macquarie Group Ltd. (2.48%), Norges Bank (1.92%), Fiera Capital Corp (1.85%) and Geode Capital Management LLC (1.74%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends.

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FOLD stock can currently be purchased for approximately $11.14.

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.15 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

The company employs 496 workers across the globe.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.